Why Is Celldex Therapeutics Stock Falling Today - Celldex Therapeutics ( NASDAQ:CLDX )
Barzolvolimab cut mast cells by -36 vs. -2.7 in placebo at 12 weeks. Despite cell depletion, no symptom or endoscopic improvement in eosinophilic esophagitis. Get the exact trades and sectors to target before August's biggest earnings-driven market moves. Details here →
La-Z-Boy Posts Downbeat Q1 Results, Joins James Hardie Industries, Alcon And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Celldex Therapeutics ( NASDAQ:CLDX ) , Alcon ( NYSE:ALC )
U.S. stock futures were slightly lower this morning, with the S&P 500 futures falling around 0.1% on Wednesday. Shares of La-Z-Boy Incorporated LZB fell sharply in pre-market trading as the company reported weaker-than-expected financial results for the first quarter of fiscal 2026.
Why Rocket Pharmaceuticals Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket - Color Star Tech ( NASDAQ:ADD ) , Aspen Insurance Hldgs ( NYSE:AHL )
Shares of Rocket Pharmaceuticals, Inc. RCKT rose sharply in pre-market trading after the company disclosed that the FDA has lifted the clinical hold on the pivotal Phase 2 trial of RP-A501 for the treatment of Danon disease. Rocket Pharmaceuticals shares jumped 15.8% to $3.37 in the pre-market ...
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis ( EoE )
HAMPTON, N.J., Aug. 19, 2025 ( GLOBE NEWSWIRE ) -- Celldex Therapeutics, Inc. ( NASDAQ:CLDX ) today reported topline results from the Company's ongoing Phase 2 study of barzolvolimab in eosinophilic esophagitis ( EoE ) , a chronic inflammatory disease of the esophagus.
Celldex Therapeutics ( CLDX ) Reports Q2 Loss, Misses Revenue Estimates
Celldex (CLDX) delivered earnings and revenue surprises of +1.16% and -56.18%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
scPharmaceuticals ( SCPH ) Soars 8.8%: Is Further Upside Left in the Stock?
scPharmaceuticals (SCPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors - Avalo Therapeutics ( NASDAQ:AVTX )
WAYNE, Pa., June 18, 2025 ( GLOBE NEWSWIRE ) -- Avalo Therapeutics, Inc. AVTX, a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Rita Jain, M.D. to its Board of Directors.
Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025 - Celldex Therapeutics ( NASDAQ:CLDX )
77% of patients ( 150 mg Q4W ) treated with barzolvolimab who had angioedema at baseline were angioedema free at Week 52 Data further support barzolvolimab clinical benefit to patients with CSU HAMPTON, N.J., June 14, 2025 ( GLOBE NEWSWIRE ) -- Celldex Therapeutics, Inc.
Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025
HAMPTON, N.J., June 14, 2025 ( GLOBE NEWSWIRE ) -- Celldex Therapeutics, Inc. ( NASDAQ:CLDX ) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the Company's Phase 2 clinical trial in chronic spontaneous urticaria ( CSU ) .
Crude Oil Rises 6%; US Consumer Sentiment Surges In June - Senmiao Tech ( NASDAQ:AIHS ) , Chanson International ( NASDAQ:CHSN )
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 1% on Friday. The Dow traded down 1.17% to 42,465.24 while the NASDAQ dipped 0.55% to 19,554.01. The S&P 500 also fell, dropping, 0.54% to 6,012.88. In trading on Friday, financial stocks fell by 2.1%.
Unusual Machines, Celldex Therapeutics, RH And Other Big Stocks Moving Higher On Friday - Bunge Global ( NYSE:BG ) , AleAnna ( NASDAQ:ANNA )
U.S. stocks were lower, with the Dow Jones index falling around 600 points on Friday. Shares of Unusual Machines, Inc. UMAC rose sharply during Friday's session after the company agreed to acquire Rotor Lab in all-stock deal valued at $7 million.
Xenon Pharmaceuticals ( XENE ) Up 8.7% Since Last Earnings Report: Can It Continue?
Xenon Pharmaceuticals (XENE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors
HAMPTON, N.J., June 06, 2025 ( GLOBE NEWSWIRE ) -- Celldex Therapeutics, Inc. ( NASDAQ:CLDX ) today announced that Denice M. Torres has been elected to the company's Board of Directors.
Celldex Therapeutics ( CLDX ) Reports Q1 Loss, Lags Revenue Estimates
Celldex (CLDX) delivered earnings and revenue surprises of -8% and 62.29%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
This Kohl's Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday - Celldex Therapeutics ( NASDAQ:CLDX ) , Co-Diagnostics ( NASDAQ:CODX )
Top Wall Street analysts initiated coverage on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Canaccord Genuity analyst Edward Nash initiated coverage on Celldex Therapeutics, Inc.
Cytokinetics ( CYTK ) Moves 5.4% Higher: Will This Strength Last?
Cytokinetics (CYTK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
This Microsoft Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Amentum Holdings ( NYSE:AMTM ) , ArriVent BioPharma ( NASDAQ:AVBP )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. B. Riley Securities analyst Kalpit Patel initiated coverage on ArriVent BioPharma, Inc.
Celldex Therapeutics to Present at Upcoming Investor Conferences - Celldex Therapeutics ( NASDAQ:CLDX )
HAMPTON, N.J., March 04, 2025 ( GLOBE NEWSWIRE ) -- Celldex Therapeutics, Inc. CLDX announced today that management will participate in fireside chats at two upcoming conferences: TD Cowen 45th Annual Health Care Conference on Tuesday, March 4th at 1:50 p.m. ET
Celldex Therapeutics to Present at Upcoming Investor Conferences
HAMPTON, N.J., March 04, 2025 ( GLOBE NEWSWIRE ) -- Celldex Therapeutics, Inc. ( NASDAQ:CLDX ) announced today that management will participate in fireside chats at two upcoming conferences: ...
Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025
- CDX-622 inhibits SCF and TSLP-dependent inflammatory signatures in human skin -- Phase 1 study in healthy volunteers ongoing ...
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025
- Greatly improved patient quality of life and reduced disease impact in patients with CSU and CIndU -- 82% of CSU patients reported that symptoms no longer had an impact on their quality of life at Week 52 -- 60% of CIndU patients reported that symptoms no longer had an impact on their quality ...
Celldex Therapeutics ( CLDX ) Reports Q4 Loss, Lags Revenue Estimates
Celldex (CLDX) delivered earnings and revenue surprises of 5.33% and 24.19%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Baidu, Informatica And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Baidu ( NASDAQ:BIDU ) , AirJoule Technologies ( NASDAQ:AIRJ )
U.S. stock futures were higher this morning, with the Dow futures gaining around 50 points on Tuesday. Shares of Baidu, Inc. BIDU fell in today's pre-market trading after the company reported a 2% decline in fourth-quarter revenue.
Why Is Jasper Therapeutics Stock Trading Lower On Wednesday? - Jasper Therapeutics ( NASDAQ:JSPR )
Briquilimab showed substantial UAS7 reductions, with mean changes of over -25 at doses ≥120mg. Briquilimab demonstrated a favorable safety profile, with no dose-limiting toxicities and dose-dependent serum tryptase reductions. On Wednesday, Jasper Therapeutics, Inc.
Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis
HAMPTON, N.J., Dec. 19, 2024 ( GLOBE NEWSWIRE ) -- Celldex Therapeutics, Inc. ( NASDAQ:CLDX ) today announced that the Company has initiated a Phase 2 study of barzolvolimab in atopic dermatitis ( AD ) and that the study is actively enrolling patients.
Fate Therapeutics ( FATE ) Up 0.5% Since Last Earnings Report: Can It Continue?
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases
HAMPTON, N.J., Nov. 20, 2024 ( GLOBE NEWSWIRE ) -- Celldex Therapeutics, Inc. ( NASDAQ:CLDX ) today announced that the first patient has been dosed in the Company's Phase 1a study of CDX-622 in healthy volunteers. CDX-622 is a bispecific antibody that targets two complementary pathways that drive ...
Celldex Therapeutics ( CLDX ) Reports Q3 Loss, Tops Revenue Estimates
Celldex (CLDX) delivered earnings and revenue surprises of 7.25% and 121.60%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Merck ( MRK ) Q3 Earnings and Revenues Top Estimates
Merck (MRK) delivered earnings and revenue surprises of 4.67% and 0.65%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Intra-Cellular Therapies ( ITCI ) Reports Q3 Loss, Tops Revenue Estimates
Intra-Cellular (ITCI) delivered earnings and revenue surprises of -38.89% and 2.17%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria
HAMPTON, N.J., Oct. 26, 2024 ( GLOBE NEWSWIRE ) -- Celldex Therapeutics, Inc. ( NASDAQ:CLDX ) announced today positive results from the Company's Phase 2 clinical trial of barzolvolimab in two of the most common forms of chronic inducible urticaria ( CIndU ) -cold urticaria ( ColdU ) and ...
Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024 - Celldex Therapeutics ( NASDAQ:CLDX )
HAMPTON, N.J., Oct. 25, 2024 ( GLOBE NEWSWIRE ) -- Celldex Therapeutics, Inc.
Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024
HAMPTON, N.J., Oct. 25, 2024 ( GLOBE NEWSWIRE ) -- Celldex Therapeutics, Inc. ( NASDAQ:CLDX ) announced today that 12 week results from the Company's Phase 2 clinical trial of barzolvolimab in two of the most common forms of chronic inducible urticaria ( CIndU ) -cold urticaria ( ColdU ) and ...
EQS-News: BB Biotech: Strategic reallocation of portfolio assets progressing
BB Biotech: Strategic reallocation of portfolio assets progressing Portfolio of BB Biotech AG as at September 30, 2024 A key event during the period under review was the US Federal Reserve's decision in September to lower interest rates by 50 bps, marking its first rate cut in four years.
This HP Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - HP ( NYSE:HPQ )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Wolfe Research analyst Andy Chen downgraded the rating for Celldex Therapeutics, Inc.
CLDX Stock Down Despite Upbeat Long-Term Data From Urticaria Study
Celldex stock falls due to safety concerns related to the treatment of urticaria patients with barzolvolimab in a phase II study, despite robust efficacy data.
Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024
- 71% of patients ( 150 mg Q4W ) achieved complete response at Week 52 -- Rapid, profound and durable improvement in UAS7 as early as Week 1 with a deepening of response over 52 weeks -- Robust improvement across omalizumab-experienced/refractory/naïve disease -- Well tolerated through 52 weeks ...
Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024
HAMPTON, N.J., Sept. 16, 2024 ( GLOBE NEWSWIRE ) -- Celldex Therapeutics, Inc. ( NASDAQ:CLDX ) announced today that an abstract describing 52 week results from the Company's Phase 2 clinical trial of barzolvolimab in patients with moderate to severe chronic spontaneous urticaria ( CSU ) ...
Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024 - Celldex Therapeutics ( NASDAQ:CLDX )
HAMPTON, N.J., Sept. 16, 2024 ( GLOBE NEWSWIRE ) -- Celldex Therapeutics, Inc.
Celldex Therapeutics ( CLDX ) Reports Q2 Loss, Tops Revenue Estimates
Celldex (CLDX) delivered earnings and revenue surprises of 8.47% and 121.85%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Acadia Healthcare ( ACHC ) Beats Q2 Earnings and Revenue Estimates
Acadia Healthcare (ACHC) delivered earnings and revenue surprises of 3.41% and 1.54%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Lattice Semiconductor Posts Weak Q2 Results, Joins Symbotic, Woodward And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Lattice Semiconductor ( NASDAQ:LSCC )
U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 0.1% on Tuesday. Shares of Lattice Semiconductor Corporation LSCC fell sharply in today's pre-market trading after the company reported worse-than-expected second-quarter financial results and issued weak ...
Why F5 Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket - F5 ( NASDAQ:FFIV )
Shares of F5, Inc. FFIV shares rose sharply in today's pre-market trading after the company reported better-than-expected third-quarter financial results and raised its FY24 earnings guidance above estimates. F5 reported quarterly earnings of $3.36 per share, which beat the analyst consensus ...
Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria
- EMBARQ-CSU1 and EMBARQ-CSU 2 will enroll more than 1800 patients suffering from CSU -- Studies include both biologic naïve and experienced patients ...
Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024
- Clinically meaningful and statistically significant improvements across multiple angioedema measurements and barzolvolimab dose groups -- Sustained activity with rapid onset within 2 weeks -- Data further support barzolvolimab clinical benefit to patients with ...
Wall Street Analysts Think Celldex ( CLDX ) Could Surge 87.27%: Read This Before Placing a Bet
The mean of analysts' price targets for Celldex (CLDX) points to an 87.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis
HAMPTON, N.J., May 15, 2024 ( GLOBE NEWSWIRE ) -- Celldex Therapeutics, Inc. ( NASDAQ:CLDX ) today announced that the first patient has been dosed in the Company's Phase 2 subcutaneous study of barzolvolimab in prurigo nodularis ( PN ) .
Wall Street Analysts Believe Celldex ( CLDX ) Could Rally 67.77%: Here's is How to Trade
The consensus price target hints at a 67.8% upside potential for Celldex (CLDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Celldex Therapeutics Hits 80-Plus Relative Strength Rating Benchmark
The Relative Strength ( RS ) Rating for Celldex Therapeutics ( CLDX ) entered a new percentile Tuesday, with an increase from 80 to 83. X IBD's unique rating tracks market leadership with a 1 ( worst ) to 99 ( best ) score.
Global Radioimmunoassay Market to Grow at a Minimal CAGR of ~3% by 2030 | DelveInsight
The increasing need for radioimmunoassay is mainly driven by the rising occurrence of cancer, infectious diseases, and various other health conditions, along with a growing number of epidemics and pandemics and increasing health awareness.
